Therapeutic rescue of pathogenic asparaginyl-tRNA synthetase alleles.
Researchers rescue severe mitochondrial disease mutations in cells using RNA-based approaches, offering hope for a currently untreatable rare condition.
This Mol Ther Nucleic Acids open-access study demonstrates rescue of pathogenic NARS2 mutations underlying severe rare mitochondrial disease using suppressor tRNA and small molecule approaches that restore asparaginyl-tRNA synthetase function. The work provides proof-of-concept for a broader class of RNA-based and pharmacologic strategies targeting aminoacyl-tRNA synthetase deficiencies, conditions with no current disease-modifying therapies.
What the study was
- Study design
- Experimental translational study with functional rescue validation
- Population
- NARS2 (asparaginyl-tRNA synthetase) patient-derived cell models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Molecular therapy. Nucleic acids
Why it surfaced
Mol Ther Nucleic Acids open-access; NARS2 therapeutic rescue is novel for untreatable ultra-rare mitochondrial disease; proof-of-concept for tRNA synthetase-directed therapy; PMC full text available.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.